- Fee assured
- Verified account
Dr Mark Tuthill MB BS, BSc, PhD, MRCP is a Consultant Medical Oncologist for NHS patients at the Churchill Hospital, Oxford and sees private patients at the Nuffield Manor Hospital, in Oxford and Genesis Care Oxford. He specialises in the treatment of early and recurrent cancer with medication including immunotherapy, chemotherapy, hormones, and cancer growth inhibitors.
Dr Tuthill qualified from University College London in 2002, after completing his BSc Honours degree in Immunology and Cell Pathology in 2001. He became a member of the Royal College of Physicians (UK) in 2005. Dr Tuthill was trained in Medical Oncology in London at the Royal Marsden, Hammersmith, Charing Cross and the Chelsea and Westminster Hospitals. He was awarded a postgraduate diploma in Oncology from the Institute of Cancer Research in 2009.
He was granted a Medical Research Council (MRC) Clinical Research Fellowship in 2009 and completed his PhD studies in tumour immunology at the MRC Clinical Sciences Centre and Imperial College, London in 2014. He was appointed as a Consultant Medical Oncologist at Oxford University Hospitals NHS Foundation Trust in 2015. Dr Tuthill is a clinical ambassador for UCARE (Urology Cancer Research and Education) which is an independent charity committed to improving the treatment and care of cancer patients through research and education.
Private cancer treatment
Dr Tuthill accepts referrals for cancer treatments before or after surgery, for a second opinion and for recurrence of cancer. He is available for consultation at the Nuffield Manor Hospital, Oxford on Thursday morning, Saturday mornings, and at other times by arrangement.
He offers specialist medical treatments for early and recurrent cancers including:
Treatments provided by Dr Mark Tuthill
Having a diagnosis of cancer can be a highly stressful and difficult time for patients and their families. Dr Tuthill uses a patient-centred approach to help those suffering from cancer to review and understand their treatment options.
Chemotherapy drugs are used to kill cancer cells and can be used to prevent cancer from returning after breast, bladder, lung, and testes surgery or to treat recurrent cancer.
Immunotherapy treatments for cancer are drugs which harness the immune system to kill cancer cells. Cancer immunotherapy has revolutionised the treatment of many forms of cancer including lung cancer, kidney cancer, bladder cancer, skin cancer and may become a treatment for some forms of breast cancer.
Cancer growth inhibitors
Cancer growth inhibitors are used to treat cancers of the prostate, lung, kidney and breast. Many cancer growth inhibitors target specific cancer mutations within the cancer cells such as Herceptin in breast cancer, cancer growth receptors in kidney cancer, and the testosterone receptor in prostate cancer.
Breast cancer can be treated by lowering the female hormone oestrogen, and prostate cancer can be treated by reducing the male hormone testosterone. Often it is possible to combine cancer growth inhibitors with hormone therapy. The side-effects of these treatments can be minimised by using various techniques.
How to be referred to Dr Tuthill as a private patient
If you would like to be seen by Dr Tuthill at the Manor Hospital, Headington, please ask your GP or the Consultant involved in your care to refer you.
Appointments can be arranged by his private secretary, Debbie Stephenson, who can be contacted by telephone on 07795 663703 or by email address at email@example.com.
Referral letters can be sent by email to firstname.lastname@example.org or faxed to 01865 716531.
Areas of interest
Breast Cancer; Prostate Cancer; Bladder Cancer; Kidney Cancer; Tumour Immunology; Personalised Medicine; targeted therapies; hormone therapies for cancer; cancer growth inhibitors; Immunotherapy;
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 14 days; Clinical supervision and planning for delivery of chemotherapy cycle 1 - 21 days; Clinical supervision and planning for the delivery of chemotherapy regimens for 0 to 7 days; Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days.
Current NHS consultant posts held
Dr Tuthill works as a substantive NHS consultant at the Churchill Hospital in Oxford.
If you are an NHS patient and need to contact the NHS service for an emergency call 01865 572192.
If you have or have had breast cancer please call 01865 235273.
If you have or have had prostate, kidney, or bladder cancer you can email my administrative team on 01865 572300 or Uro.Oncology@ouh.nhs.uk.
Dr Tuthill’s research interests include tumour immunology, cancer-growth inhibitors, and novel therapeutic drug combinations for the treatment of cancer. He is a principal investigator or sub-investigator for early and late phase clinical trials in tumour types including breast cancer, urological cancers and other tumour types. His research has been presented at international meetings and published in peer reviewed medical journals. Dr Tuthill regularly attends national and international research meetings to keep his practice in line with major cancer centres around the world.
I enjoy spending time with my family, reading the economist and gardening.
Medical Research Council Clinical Research training fellowship
Certificate of merit, Clinical Pharmacology and Therapeutics, MB,BS, Finals
First Class Honours for Immunology - BSc research project
(Additional) Languages spoken
- French - Conversational
Tuthill M, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S, Newsom-Davis T, von Karsted S, Graves J, Walczak. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene. 2014; Jun 9 (In Press).
Tuthill M, Pell R, Guiliani R, Lim A, Gudi M, Contractor KB, Lewis JS, Coombes RC, Stebbing J. Peritoneal disease in breast cancer: A specific entity with an extremely poor Prognosis. Eur J Cancer. 2009; 12:2146-9.
Dr Mark H. Tuthill
Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes P, Ozzard A, Nelson M, Gazzard B, Powles T. Immunological recovery in survivors following chemotherapy for AIDS related non-Hodgkin's lymphoma. Blood, 2008: 111:3986-90.
Savage P, Kelpanides I, Tuthill M, Short D, Seckl MJ. Brain metastases in gestational
trophoblast neoplasia: An update on incidence, management and outcome. Gynecol
Oncol. 2015 Jan 15 (In Press).
Alifrangis C, O'Hanlon-Brown C, Tuthill M, Waxman J. New drugs for prostate cancer.
BJU Int. 2012;109:1801-6.
Courses offered to GPs
I am available to talk on the management of prostate cancer, kidney cancer, breast cancer, and bladder cancer.
- MBBS University College London 2002
- PhD Tumour Immunology Imperial College London 2014
- MRCP The Royal College of Physicians 2005
- BSc Immunology University College London 2001
- Advanced Communication Skills Training (Level 3) Connected for Health 2016
Reference number 6053905
Details of entry to specialist register
- CCST, 2014
Affiliations / memberships
British Medical Association
The Association of Cancer Research
The Medical Protection Society
- Genesis care Peters WaySandy Lane...
- 14:00 - 18:00
- 07895 393451
- Genesis care, Peters Way, Sandy Lane, West...
- 09:00 - 11:00
- 07895 393451
- The Nuffield Manor Hospital
- 11:00 - 13:00
- 07895 393451
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.